Author

N. Satani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

F. L. Muller· 1 shared G. Mohapatra· 1 shared J. M. Asara· 1 shared N. Hammoudi· 1 shared P. Deng· 1 shared R. A. DePinho· 1 shared Y.-H. Lin· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

F. L. Muller

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

NAD+ biosynthesis as a collateral lethality target for precision oncology

F. L. Muller, P. Deng, N. Satani, Y.-H. Lin, N. Hammoudi, G. Mohapatra, J. M. Asara, R. A. DePinho

The paper identifies NMNAT2 as a collateral lethality target in cancers with NMNAT1 deletions, showing selective toxicity in vitro and tumor eradication in vivo.

bioRxiv · Dec 13, 2022 · PreprintCancer Biology